Thomas L. Harrison

Biography

Dr. Thomas Harrison has served as one of our directors since August 2015. Dr. Harrison is a noted author and speaker and since April 2013, has served as Chairman Emeritus of Diversified Agency Services, the world’s largest group of marketing services companies, and a division of Omnicom Group, Inc. In 1987 he founded Harrison & Star Business Group, a healthcare marketing agency that was acquired by Omnicom in 1992. From 1992-1997, he served as Chairman of the Harrison & Star Group and Chairman of Diversified Healthcare Communications for Omnicom. In 1997, Dr. Harrison was appointed President of Diversified Agency Services, and in 1998 was named Chairman and Chief Executive, serving until 2011. In 1980 he began his agency career at Rolf Werner Rosenthal a mid-sized healthcare advertising agency. From 1974-1980 he served in sales and marketing roles at Pfizer. Dr. Harrison is a member of the Executive Committee of the Montefiore Hospital, a Fellow of the New York Academy of Medicine, and Governor of the New York Academy of Sciences where he sits on the Sackler Global Nutrition Committee. Dr. Harrison became partner and board member of Dipexium Pharmaceuticals in 2013 and board member of rVue, a digital out-of-home media company, in 2013. In 2014, he was appointed to the boards of Social Growth Technologies and of Fifth Street Asset Management where he serves as Chairman of the audit committee. He previously served as a board member of the New York Chapter of the Arthritis Foundation; a board member for ePocrates, a publicly traded healthcare information company, until its 2013 acquisition; and The Morgans Hotel Group (2006-2013). Dr. Harrison holds an Advanced Degree in Cell Biology and Physiology and received an Honorary Doctorate from West Virginia University in 2007. Chair, Nominations and Corporate Governance Committee Member, Compensation Committee 

Research Interest

At Zynerba Pharmaceuticals, we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs.